AGXT2: An unnegligible aminotransferase in cardiovascular and urinary systems

Xiao-Lei Hu; Mu-Peng Li; Pei-Yuan Song; Jie Tang; Xiao-Ping Chen

doi:10.1016/j.yjmcc.2017.09.010

AGXT2: An unnegligible aminotransferase in cardiovascular and urinary systems

J Mol Cell Cardiol. 2017 Dec:113:33-38. doi: 10.1016/j.yjmcc.2017.09.010. Epub 2017 Sep 29.

Authors

Xiao-Lei Hu¹, Mu-Peng Li¹, Pei-Yuan Song¹, Jie Tang², Xiao-Ping Chen³

Affiliations

¹ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
² Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. Electronic address: jietang@csu.edu.cn.
³ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. Electronic address: chenxp74@hotmail.com.

PMID: 28970090
DOI: 10.1016/j.yjmcc.2017.09.010

Abstract

Cardiovascular diseases (CVDs) and renal impairment interact in a complex and interdependent manner, which makes clarification of possible pathogenesis between CVDs and renal diseases very challenging and important. There is increasing evidence showing that both asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) play a crucial role in the development of CVDs as well as in the prediction of cardiovascular events. Also, the plasma levels of ADMA and SDMA were reported to be significantly associated with renal function. Alanine-glyoxylate aminotransferase 2 (AGXT2) is reported to be involved in ADMA and SDMA metabolism, thus deficiency in the expression or activity of AGXT2 may play a part in the progression of cardiovascular or renal diseases through affecting ADMA/SDMA levels. Here, we focused our attention on AGXT2 and discussed its potential impact on CVDs and renal diseases. Meanwhile, the review also summarized the functions and recent advances of AGXT2, as well as the clinical association studies of AGXT2 in cardiovascular and urinary systems, which might arouse the interest of researchers in these fields.

Keywords: ADMA; AGXT2; Cardiovascular diseases; Renal diseases; SDMA; SNP.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Arginine / analogs & derivatives
Arginine / metabolism
Cardiovascular Diseases / metabolism*
Cardiovascular System / metabolism*
Humans
Kidney Diseases / metabolism*
Transaminases / metabolism*

Substances

symmetric dimethylarginine
N,N-dimethylarginine
Arginine
Transaminases
Alanine-glyoxylate transaminase